✨ Free AI Report
IN8bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview IN8bio, Inc.
Research Preview

IN8bio, Inc.: Business Overview, Financials & Competitive Analysis

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies targeting solid and liquid tumors. These specialized T cells possess unique properties to differentiate between healthy and ...

Analyst-debate audio for IN8bio, Inc.

AskCyborg analysts argue the bull and bear cases for IN8bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
IN8bio, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Promising early-stage gamma-delta T cell data offset by significant liquidity and execution risks requiring near-term capital or...

Read the full analyst-debate transcript →
Industry Biotechnology - Immunotherapy / Cell Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: July 6, 2026
AI-Verified Research
30+ Page Report

Get the Latest IN8bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

IN8bio, Inc. Overview

Pro stress-test →

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies targeting solid and liquid tumors. These specialized T cells possess unique properties to differentiate between healthy and diseased tissue, using the company's DeltEx platform with allogeneic, autologous, iPSC and genetically modified approaches.

Strategic Profile

Pro stress-test →

Following a September 2024 pipeline prioritization and approximately 49% workforce reduction, the company is focusing on generating robust clinical data from INB-100, its lead candidate. INB-100 targets acute myeloid leukemia with haplo-matched allogeneic gamma-delta T cells post-hematopoietic stem cell transplant, while INB-200/400 programs evaluate autologous DeltEx DRI gamma-delta T cells for glioblastoma, with INB-600 advancing novel gamma-delta T cell engagers.

Competitive Landscape

Pro stress-test →

IN8bio competes in the immunotherapy space against established CAR-T cell developers and emerging gamma-delta T cell programs. Direct competitors include companies developing alternative T cell therapies and checkpoint inhibitors for AML and glioblastoma, though gamma-delta T cell therapy remains a less-populated niche compared to CAR-T approaches.

Industry Context

IN8bio, Inc. operates in Biotechnology - Immunotherapy / Cell Therapy.

Key facts

Founded: N/A · Headquarters: New York, US · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for IN8bio, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when IN8bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell TherapyEstablished chimeric antigen receptor T cell immunotherapies→Checkpoint InhibitorsPD-1/PD-L1 inhibitors for hematologic and solid tumors→NK Cell TherapiesNatural killer cell-based immunotherapy approaches→

Compare IN8bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

IN8bio, Inc. operates in Biotechnology - Immunotherapy / Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Immunotherapy / Cell Therapy research →
NEW · MCP server

Ask your AI assistant about IN8bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare IN8bio, Inc. and its top competitor on Cyborg Score”
“What did IN8bio, Inc. do this quarter?”
“Is IN8bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does IN8bio, Inc. do?+
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies targeting solid and liquid tumors. These specialized T cells possess unique properties to differentiate between healthy and ...
What is IN8bio, Inc.'s Cyborg Score?+
IN8bio, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are IN8bio, Inc.'s main competitors?+
Named competitors include CAR-T Cell Therapy, Checkpoint Inhibitors, NK Cell Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full IN8bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the IN8bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track IN8bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9National Bank of Pakistan9RENK Group AG9Lumentum Holdings Inc.9First Abu Dhabi Bank9The Travelers Companies, Inc.9BAE Systems plc9Arista Networks9KLA Corporation9Hermès International S.A.8Enerjisa Enerji A.Ş.8Emirates Central Cooling Systems Corporation8WALLIX Group8StealthGas Inc.8SofWave Medical Ltd.8Himalaya Shipping Ltd.8Bannerman Energy Ltd8Sembcorp Salalah Power & Water Company8MilDef Group